Biotech company Cidara is receiving up to $780 million from Johnson & Johnson in exchange for exclusive worldwide rights to the company's AVCs still in development. Jeffrey Stein, President and Chief Executive Officer of Cidara Therapeutics, joined Cheddar to discuss.